{"entity":{"id":"nct04468984","kind":"trial","name":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","aka":["TRANSFORM-2"],"tldr":"A phase 3 trial testing Navitoclax in myeloproliferative neoplasms, active and no longer recruiting.","summary":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis is a phase 3 interventional study registered as NCT04468984, led by AbbVie, and active but no longer recruiting on the registry. Official title: Randomised, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2), Incorporating Extension Arm C - Continued Access for Navitoclax to Roll Over Subjects From Studies M10-166, M16-109, M16-191, and M19-753. Planned enrolment is 330 participants (estimated). The study started in 2020-08-31 and primary completion is expected in 2025-01-29. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT04468984","url":"https://clinicaltrials.gov/study/NCT04468984"}],"tags":["ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms","primary-myelofibrosis"],"sections":[],"technologies":[],"targets":[],"drugs":["navitoclax"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04468984","phase":"3","setting":"Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2), Incorporating Extension Arm C - Continued Access for Navitoclax to Roll Over Subjects From Studies M10-166, M16-109, M16-191, and M19-753","sponsor":"AbbVie","started":"2020-08-31","startedType":"actual","enrolled":330,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04468984/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"drug":[{"id":"navitoclax","kind":"drug","name":"Navitoclax","route":"/drugs/navitoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}